Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1463047 | 0.86 | KDR (0.57) | KDRTRPV1CA1CA2CA7 | |
| SCHEMBL1463434 | 0.85 | HTR2A (0.41) | KDRCA1CA2CA9 | |
| SCHEMBL1463280 | 0.85 | KDR (0.56) | KDRTRPV1CA1CA2CA7 | |
| SCHEMBL4555014 | 0.84 | KDR (0.64) | KDRTRPV1CA1CA2CA7 | |
| SCHEMBL5950229 | 0.84 | P2RY1 (0.46) | TRPV1CA1CA2CA9 | |
| SCHEMBL5950708 | 0.83 | CA1 (0.40) | KDRCA1CA2CA9 | |
| SCHEMBL5950634 | 0.82 | CA1 (0.37) | KDRCA1CA2CA9 | |
| SCHEMBL3577666 | 0.82 | KDR (0.52) | KDRTRPV1BLM | |
| SCHEMBL4554995 | 0.81 | BRAF (0.61) | KDRTRPV1CA1CA2CA7 | |
| SCHEMBL1463337 | 0.81 | KDR (0.54) | KDRTRPV1CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160856-A1 | Diarylurea derivatives and their use as chloride channel blockers | NEUROSEARCH A/S (DK) | 2006-07-20 | — | — | US | claimed |
| US-20060160856-A1 | Diarylurea derivatives and their use as chloride channel blockers | NEUROSEARCH A/S (DK) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160856-A1 | Diarylurea derivatives and their use as chloride channel blockers | KIT, ORAI1, CACNA1C | KDR 230/4885TRPV1 8/4885CA1 1482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.